Zahir Amoura

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7320714/publications.pdf

Version: 2024-02-01

347 papers	29,879 citations	3334 91 h-index	6471 157 g-index
370 all docs	370 docs citations	370 times ranked	26387 citing authors

#	Article	IF	Citations
1	Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor. Immunity, 2009, 30, 899-911.	14.3	1,955
2	Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genetics, 1999, 22, 352-355.	21.4	1,375
3	Joint European League Against Rheumatism and European Renal Associationâ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
4	IgA dominates the early neutralizing antibody response to SARS-CoV-2. Science Translational Medicine, 2021, 13, .	12.4	840
5	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.9	664
6	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703.	1.4	589
7	Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine, 2020, 383, 1117-1128.	27.0	506
8	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, 121, 1495-1500.	1.4	479
9	Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus. Journal of Immunology, 2005, 175, 8392-8400.	0.8	416
10	The immune paradox of sarcoidosis and regulatory T cells. Journal of Experimental Medicine, 2006, 203, 359-370.	8.5	392
11	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
12	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 510-519.	9.1	366
13	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2458-2466.	6.7	352
14	CNS involvement and treatment with interferon-Î± are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood, 2011, 117, 2778-2782.	1.4	331
15	Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmunity Reviews, 2011, 10, 744-755.	5.8	298
16	Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty-three cases compared with a control group. Arthritis and Rheumatism, 2003, 48, 3207-3211.	6.7	295
17	Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 3284-3290.	6.7	274
18	Association of anti-Î²2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. American Journal of Medicine, 1992, 93, 181-186.	1.5	264

#	Article	IF	Citations
19	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAF^{V600E}-Mutated Erdheim-Chester Disease. Journal of Clinical Oncology, 2015, 33, 411-418.	1.6	238
20	Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 76-84.	6.7	237
21	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmunity Reviews, 2012, 12, 210-217.	5.8	233
22	Cardiovascular Involvement, an Overlooked Feature of Erdheim-Chester Disease. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	229
23	Pathogenesis of Takayasu's arteritis: A 2011 update. Autoimmunity Reviews, 2011, 11, 61-67.	5.8	223
24	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 2014, 124, 1119-1126.	1.4	208
25	Microbial ecology perturbation in human IgA deficiency. Science Translational Medicine, 2018, 10, .	12.4	206
26	IFNÎ± kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5294-5299.	7.1	205
27	Late-Onset Systemic Lupus Erythematosus. Medicine (United States), 2004, 83, 348-359.	1.0	204
28	Spectrum of Cardiac Lesions in BehÃ§et Disease. Medicine (United States), 2012, 91, 25-34.	1.0	199
29	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124, 3016-3019.	1.4	197
30	A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. , 2020, 343, 33-39.		193
31	Nucleosome-restricted antibodies are detected before anti-dsdna and/or antihistone antibodies in serum of mrl-mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis and Rheumatism, 1994, 37, 1684-1688.	6.7	192
32	Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 821-824.	0.9	176
33	Long-Term Outcome of Arterial Lesions in BehÃ§et Disease. Medicine (United States), 2012, 91, 18-24.	1.0	175
34	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology, 2016, 55, 291-300.	1.9	170
35	Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis and Rheumatism, 2011, 63, 1961-1971.	6.7	168
36	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. Autoimmunity Reviews, 2014, 13, 281-291.	5.8	166

#	Article	IF	Citations
37	Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus. Correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis and Rheumatism, 1997, 40, 2217-2225.	6.7	165
38	The key role of nucleosomes in lupus. Arthritis and Rheumatism, 1999, 42, 833-843.	6.7	165
39	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 ^{high} regulatory T cells in humans. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7225-7230.	7.1	164
40	Cerebral, Facial, and Orbital Involvement in Erdheim-Chester Disease: CT and MR Imaging Findings. Radiology, 2010, 255, 586-594.	7.3	160
41	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Annals of the Rheumatic Diseases, 2013, 72, 1786-1792.	0.9	160
42	Kikuchi-Fujimoto Disease. Medicine (United States), 2014, 93, 372-382.	1.0	160
43	Is ¹⁸Fâ€fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in takayasu arteritis?. Arthritis and Rheumatism, 2009, 60, 1193-1200.	6.7	157
44	Efficacy of Biological-Targeted Treatments in Takayasu Arteritis. Circulation, 2015, 132, 1693-1700.	1.6	157
45	Outcome of pregnancies in patients with anti-SSA/Ro antibodies: A study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis and Rheumatism, 2004, 50, 3187-3194.	6.7	156
46	Erdheimâ€“Chester disease. Current Opinion in Rheumatology, 2012, 24, 53-59.	4.3	156
47	Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncology, The, 2017, 18, e113-e125.	10.7	154
48	Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multipleâ€Causeâ€ofâ€Death Analysis. Arthritis and Rheumatology, 2014, 66, 2503-2511.	5.6	152
49	Variability in the efficacy of interferonâ€Î± in Erdheimâ€Chester disease by patient and site of involvement: Results in eight patients. Arthritis and Rheumatism, 2006, 54, 3330-3336.	6.7	150
50	Systemic Capillary Leak Syndrome. American Journal of Medicine, 1997, 103, 514-519.	1.5	146
51	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood, 2017, 130, 1377-1380.	1.4	146
52	Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood, 2011, 117, 2783-2790.	1.4	144
53	Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmunity Reviews, 2005, 4, 111-115.	5.8	142
54	Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1995, 38, 1485-1491.	6.7	141

#	Article	IF	Citations
55	Takayasu Arteritis in France. Medicine (United States), 2010, 89, 1-17.	1.0	138
56	Acute Renal Infarction. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 392-398.	4.5	135
57	Anti TNF-Î± in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmunity Reviews, 2012, 11, 678-684.	5.8	132
58	Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology, 2012, 51, 557-561.	1.9	131
59	Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis and Rheumatism, 2006, 54, 184-191.	6.7	130
60	The Systemic Capillary Leak Syndrome: A Case Series of 28 Patients From a European Registry. Annals of Internal Medicine, 2011, 154, 464.	3.9	130
61	Bone Involvement in Erdheim-Chester Disease: Imaging Findings including Periostitis and Partial Epiphyseal Involvement. Radiology, 2006, 238, 632-639.	7.3	129
62	Rituximab may form a complex with iGmÎº mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virusâ€“induced vasculitis. Arthritis and Rheumatism, 2009, 60, 3848-3855.	6.7	129
63	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood, 2010, 116, 4523-4531.	1.4	126
64	Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmunity Reviews, 2015, 14, 1154-1160.	5.8	121
65	Cardiac Involvement in Erdheim-Chester Disease. Circulation, 2009, 119, e597-8.	1.6	119
66	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2176-2184.	5.6	118
67	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmunity Reviews, 2015, 14, 192-200.	5.8	118
68	Characteristics and Management of IgA Vasculitis (Henochâ€ŞschÃ¶nlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. Arthritis and Rheumatology, 2017, 69, 1862-1870.	5.6	117
69	FoxP3+ Regulatory T Cells Suppress Early Stages of Granuloma Formation but Have Little Impact on Sarcoidosis Lesions. American Journal of Pathology, 2009, 174, 497-508.	3.8	116
70	Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon-Î³ production in patients with active disease. Arthritis and Rheumatism, 2011, 63, 1698-1706.	6.7	116
71	Lupus enteritis: from clinical findings to therapeutic management. Orphanet Journal of Rare Diseases, 2013, 8, 67.	2.7	116
72	Pulmonary involvement in Erdheimâ€Chester disease: A singleâ€center study of thirtyâ€four patients and a review of the literature. Arthritis and Rheumatism, 2010, 62, 3504-3512.	6.7	114

#	Article	IF	Citations
73	Characteristics and Long-Term Outcome of 15 Episodes of Systemic Lupus Erythematosus-Associated Hemophagocytic Syndrome. Medicine (United States), 2006, 85, 169-182.	1.0	112
74	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Annals of the Rheumatic Diseases, 2016, 75, 1009-1015.	0.9	112
75	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. PLoS Pathogens, 2011, 7, e1002328.	4.7	111
76	Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. Journal of Rheumatology, 2002, 29, 2571-6.	2.0	111
77	Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis and Rheumatism, 2002, 46, 1123-1124.	6.7	110
78	Erdheimâ€“Chester Disease. Current Rheumatology Reports, 2014, 16, 412.	4.7	110
79	Pathogenesis of relapsing polychondritis: A 2013 update. Autoimmunity Reviews, 2014, 13, 90-95.	5.8	110
80	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. European Respiratory Journal, 2013, 42, 1271-1282.	6.7	108
81	Epidemiology of Primary SjÃ¶gren's Syndrome in a French Multiracial/Multiethnic Area. Arthritis Care and Research, 2014, 66, 454-463.	3.4	107
82	Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. Autoimmunity Reviews, 2014, 13, 1082-1089.	5.8	106
83	Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. Journal of Experimental Medicine, 2005, 201, 1999-2010.	8.5	105
84	Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report. Cardiology, 2007, 107, 73-80.	1.4	103
85	Anakinra in Adultâ€Onset Still's Disease: Longâ€Term Treatment in Patients Resistant to Conventional Therapy. Arthritis Care and Research, 2013, 65, 822-826.	3.4	103
86	Efficacy of interferon alfa-2a in severe and refractory uveitis associated with BehÃ§et's disease. Ocular Immunology and Inflammation, 2000, 8, 293-301.	1.8	101
87	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmunity Reviews, 2017, 16, 743-749.	5.8	101
88	Renal toxicities associated with pembrolizumab. CKJ: Clinical Kidney Journal, 2019, 12, 81-88.	2.9	101
89	Erdheim-Chester disease. Blood, 2020, 135, 1311-1318.	1.4	99
90	Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNRG as a bronchial autoantigen. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4396-4401.	7.1	98

#	Article	IF	Citations
91	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood, 2017, 130, 176-180.	1.4	98
92	High prevalence of myeloid neoplasms in adults with nonâ€“Langerhans cell histiocytosis. Blood, 2017, 130, 1007-1013.	1.4	98
93	¹⁸Fâ€fluorodeoxyglucoseâ€“positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheimâ€Chester disease. Arthritis and Rheumatism, 2009, 60, 3128-3138.	6.7	94
94	Peripheral Neuropathies Associated With Primary SjÃ¶gren Syndrome. Medicine (United States), 2011, 90, 133-138.	1.0	94
95	Phenotypes and survival in Erdheimâ€Chester disease: Results from a 165â€patient cohort. American Journal of Hematology, 2018, 93, E114-E117.	4.1	94
96	Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. European Respiratory Journal, 2013, 41, 115-122.	6.7	93
97	Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Annals of the Rheumatic Diseases, 2020, 79, 339-346.	0.9	93
98	QuantiFERON-TB Gold Cut-off Value: Implications for the Management of Tuberculosis-Related Ocular Inflammation. American Journal of Ophthalmology, 2011, 152, 433-440.e1.	3.3	92
99	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. JAMA Dermatology, 2013, 149, 935.	4.1	91
100	Erdheim-Chester Disease. Rheumatic Disease Clinics of North America, 2013, 39, 299-311.	1.9	91
101	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Annals of the Rheumatic Diseases, 2012, 71, 1227-1234.	0.9	90
102	Inflammatory Myopathies With Anti-Ku Antibodies. Medicine (United States), 2012, 91, 95-102.	1.0	90
103	Long-term outcomes of refractory neurosarcoidosis treated with infliximab. Journal of Neurology, 2017, 264, 891-897.	3.6	90
104	Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1279-1282.	2.5	88
105	Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. Journal of the American Academy of Dermatology, 2015, 72, 634-639.	1.2	87
106	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. Journal of Allergy and Clinical Immunology, 2019, 143, 1575-1585.e4.	2.9	86
107	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis and Rheumatism, 2010, 62, 2047-2054.	6.7	85
108	Lupus Anticoagulant-Hypoprothrombinemia Syndrome. Medicine (United States), 2012, 91, 251-260.	1.0	85

#	Article	IF	Citations
109	Binding of nucleosomes to a cell surface receptor: Redistribution and endocytosis in the presence of lupus antibodies. European Journal of Immunology, 1996, 26, 472-486.	2.9	84
110	Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-Î±. Seminars in Arthritis and Rheumatism, 2012, 41, 907-913.	3.4	83
111	Treatment of neurosarcoidosis. Neurology, 2016, 87, 2517-2521.	1.1	82
112	Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. Seminars in Arthritis and Rheumatism, 2017, 47, 288-294.	3.4	81
113	Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. Journal of Rheumatology, 2017, 44, 24-32.	2.0	80
114	Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmunity Reviews, 2014, 13, 730-735.	5.8	79
115	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. Best Practice and Research in Clinical Rheumatology, 2016, 30, 316-333.	3.3	79
116	Late-Onset Systemic Lupus Erythematosus. Drugs and Aging, 2012, 29, 181-189.	2.7	78
117	The role of nucleosomes in lupus. Current Opinion in Rheumatology, 2000, 12, 369-373.	4.3	76
118	Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Research, 2005, 7, 69.	2.0	75
119	Imatinib mesylate for platelet-derived growth factor receptor-betaâ€“positive Erdheim-Chester histiocytosis. Blood, 2008, 111, 5413-5415.	1.4	74
120	Erdheim-Chester disease: CT findings of thoracic involvement. European Radiology, 2010, 20, 2579-2587.	4.5	74
121	Spinal Cord Sarcoidosis. Medicine (United States), 2010, 89, 133-140.	1.0	73
122	Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis and Rheumatism, 2004, 50, 1549-1560.	6.7	72
123	Medical and developmental risk factors of catatonia in children and adolescents: A prospective caseâ€“control study. Schizophrenia Research, 2012, 137, 151-158.	2.0	72
124	Primary Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage-Adrenal Infarction in the Antiphospholipid Syndrome: Long-Term Outcome of 16 Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3179-3189.	3.6	72
125	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. Autoimmunity Reviews, 2012, 12, 204-209.	5.8	71
126	SjÃ¶gren Sensory Neuronopathy (SjÃ¶gren Ganglionopathy). Medicine (United States), 2016, 95, e3632.	1.0	71

#	Article	IF	Citations
127	Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheumatic Disease Clinics of North America, 2004, 30, 529-558.	1.9	69
128	Annual direct medical cost of active systemic lupus erythematosus in five European countries. Annals of the Rheumatic Diseases, 2014, 73, 154-160.	0.9	68
129	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151.	0.8	68
130	Quantitative radioligand assays using de novoâ€“synthesized recombinant autoantigens in connective tissue diseases: New tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases. Arthritis and Rheumatism, 2000, 43, 689.	6.7	67
131	Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients. Arthritis and Rheumatism, 2009, 61, 577-582.	6.7	67
132	Renal effects of immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2017, 32, gfw382.	0.7	67
133	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	3.8	66
134	Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain, 2006, 129, 986-995.	7.6	65
135	Clinical Phenotypes of Patients with Anti-DFS70/LEDGF Antibodies in a Routine ANA Referral Cohort. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	65
136	BRAF Mutations in Erdheim-Chester Disease. Journal of Clinical Oncology, 2013, 31, 398-398.	1.6	65
137	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (United States), 2016, 95, e3748.	1.0	64
138	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. Journal of the American Academy of Dermatology, 2016, 74, 513-520.	1.2	64
139	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis and Rheumatism, 2012, 64, 2746-2752.	6.7	63
140	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	5.8	62
141	Longâ€term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Movement Disorders, 2011, 26, 2422-2427.	3.9	61
142	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 575-583.	0.9	61
143	Blockade of Interferonâ€Î³ Normalizes Interferonâ€Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2713-2722.	5.6	60
144	Association of the R92QTNFRSF1Amutation and extracranial deep vein thrombosis in patients with BehÃ§et's disease. Arthritis and Rheumatism, 2005, 52, 608-611.	6.7	58

#	Article	IF	Citations
145	Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects. Drugs, 2015, 75, 835-846.	10.9	58
146	Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology, 2015, 54, 940-949.	1.9	58
147	Diabetes mellitus after abdominal radiation therapy. Lancet, The, 1995, 346, 633-634.	13.7	57
148	drug-induced hemophagocytosis. American Journal of Medicine, 2002, 112, 592-593.	1.5	57
149	Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. Contraception, 2011, 83, 229-237.	1.5	57
150	Anetoderma and its prothrombotic abnormalities. Journal of the American Academy of Dermatology, 2003, 49, 1008-1012.	1.2	56
151	Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis and Rheumatism, 2004, 50, 3260-3264.	6.7	56
152	Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology, 2011, 50, 2283-2289.	1.9	56
153	Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology, 2013, 52, 1635-1641.	1.9	56
154	The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission. Critical Care Medicine, 2017, 45, 1216-1223.	0.9	56
155	Efficacy and safety of rituximab for systemic lupus erythematosusâ€associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. American Journal of Hematology, 2018, 93, 424-429.	4.1	56
156	Efficacy of the <scp>MEK</scp> inhibitor cobimetinib for wildâ€type <scp>BRAF</scp> Erdheimâ€Chester disease. British Journal of Haematology, 2018, 180, 150-153.	2.5	55
157	Calreticulin, a Potential Cell Surface Receptor Involved in Cell Penetration of Anti-DNA Antibodies. Journal of Immunology, 2001, 166, 6423-6429.	0.8	54
158	Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1393-1398.	4.8	54
159	Phenotype-Haplotype Correlation of IRF5 in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. Journal of Rheumatology, 2010, 37, 987-992.	2.0	54
160	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Science and Medicine, 2014, 1, e000027.	2.7	54
161	Bilateral Adrenal Infiltration in Erdheim-Chester Disease. Report of Seven Cases and Literature Review. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2007-2012.	3.6	53
162	Ocular Whipple's Disease: Therapeutic Strategy and Long-Term Follow-Up. Ophthalmology, 2012, 119, 1465-1469.	5.2	53

#	Article	IF	Citations
163	Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. American Journal of Medicine, 2017, 130, 1219.e19-1219.e27.	1.5	53
164	Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child and Adolescent Psychiatry and Mental Health, 2011, 5, 15.	2.5	52
165	IFN-Î± and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18995-19000.	7.1	52
166	A New Presentation of Neonatal Lupus: 5 Cases of Isolated Mild Endocardial Fibroelastosis Associated with Maternal Anti-SSA/Ro and Anti-SSB/La Antibodies. Journal of Rheumatology, 2011, 38, 378-386.	2.0	51
167	Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome?. Rheumatology International, 2012, 32, 3285-3290.	3.0	51
168	Study of Anti-MÃ¼llerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3785-3792.	3.6	51
169	SjÃ¶gren Syndrome-Associated Small Fiber Neuropathy. Medicine (United States), 2013, 92, e10-e18.	1.0	51
170	Potentiation of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone. Annals of Internal Medicine, 2000, 132, 631.	3.9	49
171	Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis and Rheumatism, 2003, 48, 3487-3496.	6.7	49
172	In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	49
173	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood, 2016, 127, 1509-1512.	1.4	49
174	Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-Î³ monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Science and Medicine, 2017, 4, e000226.	2.7	49
175	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. Clinical Pharmacokinetics, 2008, 47, 277-284.	3.5	48
176	Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use. Journal of Rheumatology, 2012, 39, 1835-1839.	2.0	48
177	Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmunity Reviews, 2016, 15, 994-1000.	5.8	48
178	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheimâ€“Chester Disease,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (Desto Oncology Reports, 2019, 21, 62.	4.0	48
179	Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Annals of the Rheumatic Diseases, 2011, 70, 1695-1696.	0.9	46
180	The role of B-mode ultrasonography and electron beam computed tomography in evaluation of Takayasu's arteritis: A study of 43 patients. Seminars in Arthritis and Rheumatism, 2000, 30, 25-32.	3.4	45

#	Article	IF	Citations
181	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. Arthritis and Rheumatism, 2011, 63, 2091-2096.	6.7	45
182	Pseudotumoural presentation of neuro-Behcet's disease: case series and review of literature. Rheumatology, 2012, 51, 1216-1225.	1.9	45
183	LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology, 2012, 51, 1906-1915.	1.9	43
184	Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis and Rheumatism, 2011, 63, 3502-3511.	6.7	42
185	Active immunisation of human interferon Î± transgenic mice with a human interferon Î± Kinoid induces antibodies that neutralise interferon Î± in sera from patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 1138-1143.	0.9	41
186	Small vessel involvement in Takayasu's arteritis. Autoimmunity Reviews, 2013, 12, 355-362.	5.8	41
187	Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. Clinical Rheumatology, 2014, 33, 1209-1215.	2.2	41
188	Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. Arthritis and Rheumatism, 2011, 63, 1136-1140.	6.7	39
189	Absence ofMycobacterium tuberculosisin Arterial Lesions from Patients with Takayasuâ€™s Arteritis. Journal of Rheumatology, 2009, 36, 1682-1685.	2.0	38
190	The histiocytosis Erdheimâ€“Chester disease is an inflammatory myeloid neoplasm. Expert Review of Clinical Immunology, 2015, 11, 1033-1042.	3.0	38
191	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212705.	0.9	38
192	Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000785.	3.8	38
193	Erdheim-Chester Disease: a Concise Review. Current Rheumatology Reports, 2019, 21, 66.	4.7	38
194	Ovarian vein thrombosis in the antiphospholipid syndrome. Arthritis and Rheumatism, 2004, 50, 183-186.	6.7	37
195	Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0143689.	2.5	37
196	Ultraviolet light converts propranolol, a nonselective Î²â€blocker and potential lupusâ€inducing drug, into a proinflammatory AhR ligand. European Journal of Immunology, 2015, 45, 3174-3187.	2.9	36
197	Case Study: Effectiveness of Plasma Exchange in an Adolescent With Systemic Lupus Erythematosus and Catatonia. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 497-499.	0.5	35
198	Ultrasound, Elastography, and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Riedel's Thyroiditis: Report of Two Cases. Thyroid, 2011, 21, 799-804.	4.5	35

#	Article	IF	Citations
199	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 997-1003.	2.0	35
200	Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. Joint Bone Spine, 2010, 77, 4-5.	1.6	34
201	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica, 2020, 105, e5-e8.	3.5	34
202	Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro-Oncology, 2021, 23, 1433-1446.	1.2	33
203	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
204	Hydroxychloroquine in systemic lupus erythematosus. Lancet, The, 2007, 369, 1257-1258.	13.7	31
205	Plasma Exchange in Patients with Stuporous Catatonia and Systemic Lupus Erythematosus. Psychotherapy and Psychosomatics, 2008, 77, 195-196.	8.8	31
206	Cerebrovascular events in Takayasu arteritis: a multicenter case-controlled study. Journal of Neurology, 2018, 265, 757-763.	3.6	31
207	The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmunity Reviews, 2011, 10, 674-678.	5.8	30
208	Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature. Immunologic Research, 2017, 65, 375-385.	2.9	30
209	Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000783.	3.8	30
210	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	1.4	30
211	Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology, 2014, 83, 1294-1296.	1.1	29
212	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: Comment on the article by Lazzerini et al. Arthritis and Rheumatism, 2005, 52, 676-677.	6.7	28
213	Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Annals of the Rheumatic Diseases, 2007, 66, 1547-1548.	0.9	28
214	Symptomatic muscular sarcoidosis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e452.	6.0	27
215	Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica, 2019, 104, e97-e99.	3.5	27
216	High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica, 2006, 91, 1121-5.	3.5	26

#	Article	IF	Citations
217	Skeletal muscle lymphoma in patients with the acquired immunodeficiency syndrome: a diagnostic challenge. Arthritis and Rheumatism, 1993, 36, 426-427.	6.7	25
218	SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome (Clarkson's) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.5	24
219	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 1420-1427.	0.9	24
220	Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: a report of three cases. Lupus, 1999, 8, 482-485.	1.6	23
221	Clinicopathological features of multiple mononeuropathy associated with systemic lupusÂerythematosus: a multicenter study. Journal of Neurology, 2017, 264, 1218-1226.	3.6	23
222	Characteristics, outcome and treatments with cranial pachymeningitis. Medicine (United States), 2018, 97, e11413.	1.0	23
223	Gastrointestinal involvement in adult IgA vasculitis (Henoch-SchÃ¶nlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. Rheumatology, 2020, 59, 3050-3057.	1.9	23
224	Lower Rate of Daily Smokers With Symptomatic COVID-19: A Monocentric Self-Report of Smoking Habit Study. Frontiers in Medicine, 2021, 8, 668995.	2.6	23
225	Early anti-nucleosome autoantibodies from a single MRLâ€‰+/+ mouse: fine specificity, V gene structure and pathogenicity. European Journal of Immunology, 1998, 28, 3411-3422.	2.9	22
226	Association Study of ITGAM, ITGAX, and CD58 Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. Journal of Rheumatology, 2011, 38, 1033-1038.	2.0	22
227	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. Journal of the American Academy of Dermatology, 2015, 73, e29-e30.	1.2	22
228	Efficacy of infliximab in the treatment of Erdheim-Chester disease. Annals of the Rheumatic Diseases, 2018, 77, 1387-1390.	0.9	22
229	Central nervous system involvement in Erdheim-Chester disease. Neurology, 2020, 95, e2746-e2754.	1.1	22
230	Epithelioid sarcoma mimicking abscess: review of the MRI appearances. Skeletal Radiology, 2001, 30, 173-177.	2.0	21
231	Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: Clinical and immunological features: A propos of 40 new cases and review of the literature. Autoimmunity Reviews, 2010, 9, 652-656.	5.8	21
232	Central nervous system angiitis: a series of 31 patients. Clinical Rheumatology, 2014, 33, 105-110.	2.2	21
233	IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000787.	3.8	21
234	Evolution of Nutritional Status after Early Nutritional Management in COVID-19 Hospitalized Patients. Nutrients, 2021, 13, 2276.	4.1	21

#	Article	IF	Citations
235	Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. Neurology, 2002, 59, 1468-1469.	1.1	20
236	Mononeuropathy multiplex associated with acute parvovirus B19 infection: characteristics, treatment and outcome. Journal of Neurology, 2011, 258, 1321-1326.	3.6	20
237	Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells. Oncotarget, 2017, 8, 104733-104744.	1.8	20
238	Multiparameter grouping delineates heterogeneous populations of human ILâ€17 and/or ILâ€22 Tâ€cell producers that share antigen specificities with other Tâ€cell subsets. European Journal of Immunology, 2011, 41, 2596-2605.	2.9	19
239	Type B Insulin-resistance syndrome: a cause of reversible autoimmune hypoglycaemia. Lancet, The, 2014, 384, 1548.	13.7	19
240	A causality algorithm to guide diagnosis and treatment of catatonia due to autoimmune conditions in children and adolescents. Schizophrenia Research, 2018, 200, 68-76.	2.0	19
241	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	3.8	19
242	Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study. PLoS ONE, 2012, 7, e42418.	2.5	19
243	Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. Joint Bone Spine, 2007, 74, 446-452.	1.6	18
244	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. Journal of Neurology, 2019, 266, 1073-1078.	3.6	18
245	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. Arthritis Research and Therapy, 2020, 22, 223.	3.5	18
246	HTLV-1-associated inflammatory myopathies: Low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. Journal of Clinical Virology, 2013, 57, 70-76.	3.1	17
247	Thrombophilia Associated with Anti-DFS70 Autoantibodies. PLoS ONE, 2015, 10, e0138671.	2.5	17
248	Lung Involvement in Destombes-Rosai-Dorfman Disease. Chest, 2020, 157, 323-333.	0.8	17
249	Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-BarrÃ© Syndrome. PLoS ONE, 2008, 3, e2109.	2.5	17
250	Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren's syndrome. Rheumatology, 2011, 50, 1175-1176.	1.9	16
251	Catatonia and Autoimmune Conditions in Children and Adolescents: Should We Consider a Therapeutic Challenge?. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 167-176.	1.3	15
252	Hypoalphalipoproteinemia andBRAF^{V600E}Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1913-1925.	2.4	15

#	Article	IF	Citations
253	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. Haematologica, 2019, 104, e502-e505.	3.5	15
254	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheimâ€“Chester disease. OncoImmunology, 2016, 5, e1181244.	4.6	14
255	Aortic involvement in relapsing polychondritis. Joint Bone Spine, 2018, 85, 345-351.	1.6	14
256	Lupus and vaccinations. Current Opinion in Rheumatology, 2018, 30, 465-470.	4.3	14
257	Development and Validation of a Fast Ultra-High Performance Liquid Chromatographyâ€“Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. Therapeutic Drug Monitoring, 2019, 41, 476-482.	2.0	14
258	Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatology, 2022, 61, 4355-4363.	1.9	14
259	Anticancer Drug-Induced Capillary Leak Syndrome. Kidney International Reports, 2022, 7, 945-953.	0.8	14
260	Chronic Malaria Revealed by a New Fluorescence Pattern on the Antinuclear Autoantibodies Test. PLoS ONE, 2014, 9, e88548.	2.5	13
261	Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. Annals of the Rheumatic Diseases, 2014, 73, 474-475.	0.9	12
262	Detection in whole blood of autoantibodies for the diagnosis of connective tissue diseases in near patient testing condition. PLoS ONE, 2018, 13, e0202736.	2.5	12
263	Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort. Rheumatology, 2020, 59, 1398-1406.	1.9	12
264	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). Arthritis Research and Therapy, 2021, 23, 70.	3.5	12
265	F-18 FDG-PET/CT in aseptic abscesses with recurrent febrile abdominal pain. Scandinavian Journal of Gastroenterology, 2011, 46, 577-582.	1.5	11
266	162 Active Anti-IFN Î± Immunotherapy Applied to Chronic Viral and Autoimmune Diseases. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 68.	2.1	11
267	Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes. Journal of Allergy and Clinical Immunology, 2018, 141, 1539-1540.	2.9	11
268	Cerebrovascular events are associated with lower survival in giant cell arteritis: A case-controlled multicenter study. Joint Bone Spine, 2018, 85, 383-385.	1.6	11
269	Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations. Lupus Science and Medicine, 2020, 7, e000399.	2.7	11
270	Psychiatric autoimmune conditions in children and adolescents: Is catatonia a severity marker?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110028.	4.8	11

#	Article	IF	Citations
271	Cerebral pseudo-tumoral neuro-Behcet: Histological demonstration of an inflammatory and vascular disease. Clinical Neurology and Neurosurgery, 2017, 161, 48-50.	1.4	10
272	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis-related Bronchiectasis: Data from 61 Patients. Journal of Rheumatology, 2020, 47, 1522-1531.	2.0	10
273	New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. Clinical Rheumatology, 2021, 40, 1933-1940.	2.2	10
274	Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 633658.	4.8	10
275	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. Frontiers in Immunology, 2022, 13, 790334.	4.8	10
276	Whole-body MRI in Erdheim-Chester disease. Rheumatology, 2012, 51, 948-950.	1.9	9
277	Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology, 2021, 60, 4245-4251.	1.9	9
278	Systemic lupus erythematosus in patients native to West and Central Africa: Comment on the article by Bae et al. Arthritis and Rheumatism, 1999, 42, 1560-1561.	6.7	8
279	Successful Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock Due to the Catastrophic Antiphospholipid Syndrome. Annals of Internal Medicine, 2010, 153, 487.	3.9	8
280	Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. Kidney International Reports, 2021, 6, 526-528.	0.8	8
281	Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus. Scientific Reports, 2021, 11, 7893.	3.3	8
282	Anti-Î²2-Glycoprotein I antibodies and thrombosis. Clinical Reviews in Allergy and Immunology, 1995, 13, 67-72.	6.5	7
283	Spinal Koebner phenomenon: Medullar sarcoidosis facing a discal hernia. Joint Bone Spine, 2017, 84, 497-498.	1.6	7
284	Expanding the spectrum of HIV-associated myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1296-1298.	1.9	7
285	Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. Nephrology Dialysis Transplantation, 2020, 35, 1721-1729.	0.7	7
286	Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells. Annals of the Rheumatic Diseases, 2020, 79, 1522-1524.	0.9	6
287	Highly sensitive serum cardiac troponin T and cardiovascular events in patients with systemic lupus erythematosus (TROPOPLUS study). Rheumatology, 2021, 60, 1210-1215.	1.9	6
288	The consequences of COVID-19 pandemic on patients with monoclonal gammopathyâ€“associated systemic capillary leak syndrome (Clarkson disease). Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 626-629.	3.8	6

#	Article	IF	Citations
289	Human lupus, fewer Treg cells indeed: Comment on the article by Venigalla et al. Arthritis and Rheumatism, 2009, 60, 630-630.	6.7	5
290	Interferon-Alpha in Cardiac Erdheim-Chester Disease. Journal of the American College of Cardiology, 2011, 58, 2695.	2.8	5
291	Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis. European Journal of Internal Medicine, 2011, 22, e80-e86.	2.2	5
292	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheimâ€“Chester Disease. Cancers, 2020, 12, 3240.	3.7	5
293	Clarksonâ€™s Disease Episode or Secondary Systemic Capillary Leak-Syndrome. Chest, 2021, 159, 441.	0.8	5
294	Hyperthyroidism-associated chorea. Lancet, The, 1998, 352, 239.	13.7	4
295	Spontaneous remission of fully symptomatic visceral leishmaniasis. BMC Infectious Diseases, 2015, 15, 445.	2.9	4
296	Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report. Journal of Medical Case Reports, 2017, 11, 58.	0.8	4
297	Catastrophic antiphospholipid syndrome (CAPS)-induced ischemic pancreatic ducts injury mimicking intraductal papillary mucinous neoplasm (IPMN). Seminars in Arthritis and Rheumatism, 2018, 47, 565-568.	3.4	4
298	Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. Journal of the American Academy of Dermatology, 2022, 87, 323-332.	1.2	4
299	Severe Libmanâ€“Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases. Rheumatology, 2023, 62, 707-715.	1.9	4
300	â€œCatastrophicâ€•Diagnosis of the Antiphospholipid Syndrome. Annals of Internal Medicine, 1999, 131, 798-799.	3.9	3
301	Lupus band test yields negative results in primary antiphospholipid syndrome. Arthritis and Rheumatism, 2001, 44, 488-489.	6.7	3
302	mTOR: a new target in Erdheim-Chester disease?. Blood, 2015, 126, 1151-1152.	1.4	3
303	Long-bones involvement in generalized crystal-storing histiocytosis. Joint Bone Spine, 2019, 86, 652-653.	1.6	3
304	Handling shock in idiopathic systemic capillary leak syndrome (Clarksonâ€™s disease): less is moreâ€”comment. Internal and Emergency Medicine, 2020, 15, 347-348.	2.0	3
305	Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study. Frontiers in Immunology, 2020, 11, 597863.	4.8	3
306	Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort. Blood, 2016, 128, 2542-2542.	1.4	3

#	Article	IF	Citations
307	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. Blood, 2016, 128, 951-951.	1.4	3
308	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia, 2021, , .	7.2	3
309	The presence of atherosclerotic plaques in patients with Takayasu arteritis: Comment on the article by Keenan et al. Arthritis and Rheumatism, 2010, 62, 1558-1559.	6.7	2
310	Antimalarials and SLE. , 2011, , 1061-1081.		2
311	Preventing Relapses in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. JAMA - Journal of the American Medical Association, 2011, 305, 996.	7.4	2
312	A 75-Year-Old Woman Admitted to the ICU With Respiratory Failure. Chest, 2012, 142, 1063-1067.	0.8	2
313	Traitement du lupus Ã©rythÃ©mateux systÃ©mique. , 2013, , 73-90.		2
314	Neurodegeneration in histiocytoses might start in utero. Lancet Neurology, The, 2017, 16, 953-954.	10.2	2
315	Response to: â€˜Implications of SARS-CoV-2 infection for patients with rheumatic diseaseâ€™ by Linet al. Annals of the Rheumatic Diseases, 2022, 81, e153-e153.	0.9	2
316	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. Autoimmunity Reviews, 2021, 20, 102874.	5.8	2
317	Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease. Pancreas, 2021, 50, e6-e8.	1.1	2
318	High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment. Blood, 2019, 134, 2324-2324.	1.4	2
319	Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study. Journal of Internal Medicine, 2022, 292, 536-539.	6.0	2
320	Activated protein C and pulmonary embolism. Lancet, The, 1996, 347, 1841-1842.	13.7	1
321	Recurrent Myocardial Infarction in a Patient With Paroxysmal Nocturnal Hemoglobinuria. Circulation, 2003, 108, e91-2.	1.6	1
322	Letter by Guettrot-Imbert et al Regarding Article, â€œEarly Diagnosis and Treatment of Atrioventricular Block in the Fetus Exposed to Maternal Anti-SSA/Ro-SSB/La Antibodiesâ€• Circulation, 2009, 120, e167; author reply e168.	1.6	1
323	Atypical dementia. Lancet, The, 2010, 376, 656.	13.7	1
324	Survival analysis versus event count. Annals of the Rheumatic Diseases, 2014, 73, e37-e37.	0.9	1

#	Article	IF	Citations
325	Reversible Severe Eosinophilic Endomyocardial Fibrosis During Pregnancy. Medicine (United States), 2015, 94, e1307.	1.0	1
326	Response to: â€˜Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester diseaseâ€™ by Campochiaro et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2019-216755.	0.9	1
327	Cutaneous Kikuchi disease-like inflammatory pattern without lymph node involvement is associated with systemic disease and severe features in lupus erythematous: A case-control study. Lupus, 2021, 30, 473-477.	1.6	1
328	ECLIPSE: a French Study Concerning the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2010, 116, 5134-5134.	1.4	1
329	Can Rituximab be Useful for Treating SLE-Associated Immune Cytopenias ? Results from a Retrospective Multicentre Study on 62 Patients. Blood, 2016, 128, 870-870.	1.4	1
330	Potentialisation deÂlaÂfluindione etÂdeÂlaÂwarfarine parÂlaÂdexamÃ©thasone dansÂleÂmyÃ©lome multiple etÂl'amylose AL. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 845-851.	0.0	0
331	Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: Comment on the article by Koneru et al. Arthritis and Rheumatism, 2008, 59, 153-153.	6.7	0
332	The Systemic Capillary Leak Syndrome. Annals of Internal Medicine, 2011, 155, 335.	3.9	0
333	Predictive value and clinical interest of the antiphospholipid score: Comment on the article by Otomo et al. Arthritis and Rheumatism, 2012, 64, 2806-2807.	6.7	0
334	Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 214, 201-203.	1.1	0
335	Atteintes ostÃ©oarticulaires au cours des histiocytoses. Revue Du Rhumatisme Monographies, 2019, 86, 120-125.	0.0	0
336	02â€…Management of difficult infections in SLE. , 2019, , .		0
337	SAT0188â€…WHOLE BLOOD VERSUS SERUM HYDROXYCHLOROQUINE LEVELS FOR DRUG MONITORING OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS OF A PHARMACOLOGICAL STUDY. , 2019, , .		0
338	Neurosarcoidosis. , 2019, , 115-125.		0
339	Response to: â€˜Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial"â€™ by Mousavi and Taherifard. Annals of the Rheumatic Diseases, 2022, 81, e47-e47.	0.9	0
340	Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. Blood, 2010, 116, 4716-4716.	1.4	0
341	Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study. Blood, 2014, 124, 3254-3254.	1.4	0
342	Pulmonary Involvement in Takayasu Arteritis and BehÃ§et Disease. , 2015, , 177-190.		0

#	Article	IF	Citations
343	Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease.. Journal of Clinical Oncology, 2016, 34, 7069-7069.	1.6	0
344	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.. Journal of Clinical Oncology, 2016, 34, e19074-e19074.	1.6	0
345	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. Blood, 2018, 132, 4380-4380.	1.4	0
346	Erdheim-Chester disease: An orbital MRI study.. Journal of Clinical Oncology, 2022, 40, e19085-e19085.	1.6	0
347	Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.. Journal of Clinical Oncology, 2022, 40, 7059-7059.	1.6	0